Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Lessened by Diversified Trust Co

Diversified Trust Co lessened its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) by 25.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,455 shares of the pharmaceutical company’s stock after selling 493 shares during the quarter. Diversified Trust Co’s holdings in Vertex Pharmaceuticals were worth $608,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. University of Texas Texas AM Investment Managment Co. bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth $25,000. Arlington Trust Co LLC raised its position in Vertex Pharmaceuticals by 97.1% in the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 33 shares in the last quarter. Annapolis Financial Services LLC bought a new stake in Vertex Pharmaceuticals in the first quarter worth about $27,000. ICA Group Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals in the 4th quarter valued at about $28,000. Finally, Fortitude Family Office LLC bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. 90.96% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently commented on VRTX shares. HC Wainwright reissued a “buy” rating and set a $462.00 target price on shares of Vertex Pharmaceuticals in a research note on Tuesday, May 7th. Evercore ISI raised Vertex Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $438.00 price objective for the company in a research note on Thursday, April 11th. Guggenheim lifted their target price on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. Canaccord Genuity Group reaffirmed a “sell” rating and set a $371.00 target price on shares of Vertex Pharmaceuticals in a report on Friday, April 12th. Finally, Wells Fargo & Company increased their price target on Vertex Pharmaceuticals from $540.00 to $555.00 and gave the company an “overweight” rating in a research report on Monday, June 24th. Three research analysts have rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $448.61.

Check Out Our Latest Analysis on VRTX

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX opened at $470.28 on Thursday. The stock has a market capitalization of $121.36 billion, a PE ratio of 30.52, a P/E/G ratio of 2.41 and a beta of 0.39. The stock has a 50-day simple moving average of $447.69 and a 200 day simple moving average of $427.70. The company has a debt-to-equity ratio of 0.02, a quick ratio of 3.29 and a current ratio of 3.50. Vertex Pharmaceuticals Incorporated has a twelve month low of $335.82 and a twelve month high of $486.42.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The pharmaceutical company reported $4.76 EPS for the quarter, beating analysts’ consensus estimates of $3.66 by $1.10. The business had revenue of $2.69 billion during the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. The firm’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.67 earnings per share. Research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.22 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, Director Bruce I. Sachs sold 7,073 shares of Vertex Pharmaceuticals stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total transaction of $3,168,704.00. Following the completion of the transaction, the director now directly owns 40,000 shares of the company’s stock, valued at $17,920,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Vertex Pharmaceuticals news, EVP Ourania Tatsis sold 2,350 shares of Vertex Pharmaceuticals stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $439.11, for a total value of $1,031,908.50. Following the completion of the transaction, the executive vice president now owns 53,523 shares in the company, valued at approximately $23,502,484.53. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Bruce I. Sachs sold 7,073 shares of the stock in a transaction on Wednesday, May 22nd. The stock was sold at an average price of $448.00, for a total value of $3,168,704.00. Following the sale, the director now owns 40,000 shares in the company, valued at approximately $17,920,000. The disclosure for this sale can be found here. Insiders have sold 28,366 shares of company stock worth $13,058,787 over the last three months. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.